{"id":"zilovertamab-vedotin","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Anorexia"},{"rate":"5-20%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL1742994","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to CD30-positive cells and delivering a cytotoxic payload, ultimately leading to cell death. This mechanism is particularly effective in treating certain types of lymphoma and other cancers that express the CD30 antigen.","oneSentence":"Zilovertamab vedotin is a monoclonal antibody-drug conjugate that targets the CD30 antigen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:19.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory CD30-positive lymphomas"}]},"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT06395103","phase":"PHASE1, PHASE2","title":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-16","conditions":"B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma","enrollment":90},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT05562830","phase":"PHASE1, PHASE2","title":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-16","conditions":"Urothelial Carcinoma","enrollment":48},{"nctId":"NCT05458297","phase":"PHASE2","title":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-21","conditions":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma","enrollment":223},{"nctId":"NCT05144841","phase":"PHASE2","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-08","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":140},{"nctId":"NCT04504916","phase":"PHASE2","title":"A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)","status":"TERMINATED","sponsor":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2020-10-07","conditions":"Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC","enrollment":102},{"nctId":"NCT05406401","phase":"PHASE2","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-14","conditions":"Lymphoma, Large B-Cell, Diffuse (DLBCL)","enrollment":60},{"nctId":"NCT03833180","phase":"PHASE1","title":"A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)","status":"COMPLETED","sponsor":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2019-03-14","conditions":"Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma","enrollment":91}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PRODUCT USE ISSUE"},{"count":2,"reaction":"RESPIRATORY FAILURE"},{"count":2,"reaction":"SEPSIS"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"CHRONIC LYMPHOCYTIC LEUKAEMIA TRANSFORMATION"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"FUNGAL INFECTION"},{"count":1,"reaction":"NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-2140","VLS-101"],"phase":"phase_3","status":"active","brandName":"Zilovertamab vedotin","genericName":"Zilovertamab vedotin","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Zilovertamab vedotin is a monoclonal antibody-drug conjugate that targets the CD30 antigen. Used for Relapsed or refractory CD30-positive lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}